SCHEMBL4941504

SCHEMBL4941504

c1ccc(-c2ccccc2-c2ccc(-c3ccccc3-c3ccccc3)c3nc(-c4ccccc4)c(-c4ccccc4)nc23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.44
DHFR P00374 1/20 0.43
PIK3CG P48736 1/20 0.43
LMNA P02545 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HTT P42858 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
TP53 P04637 1/20 0.42
MAPK1 P28482 1/20 0.42
DCUN1D1 Q96GG9 2/20 0.42
DCUN1D2 Q6PH85 1/20 0.42
GPR55 Q9Y2T6 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 4/20 0.41
GAA P10253 3/20 0.41
HSD17B10 Q99714 3/20 0.40
HPGD P15428 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13079002 0.98 L3MBTL1 (0.43) L3MBTL1DHFRPIK3CGLMNAMEN1
SCHEMBL13078938 0.96 L3MBTL1 (0.42) L3MBTL1DHFRPIK3CGLMNAMEN1
SCHEMBL13078990 0.91 DCUN1D1 (0.42) L3MBTL1LMNAMAPK1DCUN1D1DCUN1D2
SCHEMBL13078969 0.89 L3MBTL1 (0.47) L3MBTL1DHFRPIK3CGLMNAMEN1
SCHEMBL1766035 0.89 DHFR (0.47) L3MBTL1DHFRPIK3CGLMNAMEN1
SCHEMBL13726547 0.88 NOTUM (0.50) HTTADORA2AADORA1ALDH1A1HSD17B10
SCHEMBL13726755 0.88 NOTUM (0.50) HTTADORA2AADORA1ALDH1A1HSD17B10
SCHEMBL13078966 0.87 THRB (0.42) L3MBTL1DHFRPIK3CGLMNAMEN1
SCHEMBL12207340 0.86 ADK (0.39) L3MBTL1DHFRPIK3CGLMNAMEN1
SCHEMBL6725763 0.86 ADK (0.39) L3MBTL1DHFRPIK3CGLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283052-B2 Quinoxaline derivative excellent in electron-transporting property and very effective as an electron-transporting material in a light-emitting element and the like SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-10-09 US disclosed
US-8283052-B2 Quinoxaline derivative excellent in electron-transporting property and very effective as an electron-transporting material in a light-emitting element and the like SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-10-09 US disclosed
US-8283052-B2 Quinoxaline derivative excellent in electron-transporting property and very effective as an electron-transporting material in a light-emitting element and the like SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-10-09 US disclosed
US-20080193794-A1 Quinoxaline Derivative, Light-Emitting Element, Light-Emitting Device, and Electronic Appliance SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-08-14 US disclosed
US-20080193794-A1 Quinoxaline Derivative, Light-Emitting Element, Light-Emitting Device, and Electronic Appliance SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-08-14 US disclosed
US-20080193794-A1 Quinoxaline Derivative, Light-Emitting Element, Light-Emitting Device, and Electronic Appliance SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080193794-A1 Quinoxaline Derivative, Light-Emitting Element, Light-Emitting Device, and Electronic Appliance SLC35E1, SLC1A2, ATP1A2 L3MBTL1 1735/4885DHFR 3454/4885PIK3CG 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.